Aepodia – Your Preferred Partner in Early Phase Clinical Trials : PARTNER IN FARLY PHASE®

Since its inception, Aepodia has worked to build successful partnerships to offer its customers appropriate, specialist expertise and cutting-edge services in a competitive market. We are currently involved in six collaborative R&D projects involving private, academic and public organisations throughout Europe. We place a strong emphasis on R&D, which we leverage to acquire new know-how and provide new services.

Aepodia is a partner in two FP7 research projects (Mon4strat & Myasterix).

FP7 (Seventh Framework Program for Research and Technological Development) is the EU’s main instrument for funding innovative research and development in Europe between 2007-2013.

The first European centre dedicated to translational pain research and innovation against pain.

Aepodia is a partner of the Analgesia Institute, a unique multidisciplinary platform providing R&D preclinical and clinical services fully dedicated to developing medicines targeting pain management.

Aepodia is involved in several of the Institute’s confidential research projects.

See also www.institut-analgesia.org and www.analgesiapartnership.com

Fibromyalgia & chronic facial pain

Bio-Modeling Systems and Aepodia are currently building two new CADI^TM “Computer Assisted Deductive Integration” models that describe the biological phenomena involved in fibromyalgia and chronic facial pain. The purpose of this collaboration is not only to explain the cause of the pain but also to provide new combination of molecules and therapeutic strategies for the treatment of severe pain.

See also: www.bmsystems.net

Stratified and personalised approaches to antibacterial treatment

The main objective of the MON4STRAT project is to improve β-lactam-based antibiotic therapy for critically-ill patients to move towards effective individualised treatments and reduce drug resistance (EDR) and adverse effects.

Aepodia coordinates the work on data management and is in charge of collecting, centralising, reconciling and reporting data collected in patient clinical trials performed in adults and children.

See also: www.mon4strat.ulg.ac.be

For a therapeutic vaccine

Aepodia is a partner of the Myasterix project aimed at advancing a therapeutic vaccine candidate (CV-MG01 with orphan drug status) indicated for the autoimmune disease myasthenia gravis (MG) to human proof-of-concept studies.

The aim is to offer patients an innovative targeted therapeutic approach having fewer and less severe side effects than existing therapies.

This approach will generate considerable benefits for patients and society by replacing primary and secondary costs with the sole cost of the vaccine and its straightforward three-injection procedure.

See also: www.myasterix.eu

Realistic Observations in Game and Experience in Rehabilitation

This collaborative project involves public and academic partners and is funded by the DG06 (General Operational Directorate for Economy, Employment and Research, GREENTIC call for projects).

The aim is to develop a novel assessment tool for cognitive deficits using virtual reality.

Baptised “R.O.G.E.R” (Realistic Observations in Game and Experience in Rehabilitation), the project brings together the pharmaceutical and serious gaming and academia. The initial goal of this new tool is to observe patients performing everyday tasks in a realistic environment and collect quantitative and qualitative information on their individual performance to allow possible therapeutic intervention such as awareness of disabilities, development, adjustment and convenient means of compensation, acquisition and generalisation of useful rehabilitation tools

Aepodia is a project partner alongside Fishing Cactus, Multitel  and ULB/Erasme Hospital.

See also : gdeliens.ulb.ac.be/index.php/roger-project

Personalised treatment

Personalised medicine

Tools4Patient uses multimodal approaches to develop next-generation companion diagnostics. The company’s products will accelerate the development of new treatments and provide tools for healthcare providers to personalise treatments and meet patients’ individual needs.

Aepodia is a partner of R&D programs involving oncology and chronic pain (confidential).

See also: www.tools4patients.com